PAIN RESEARCH NEWS
Research summary · full paper checked · Study published 9 September 2026 · Sources checked 10 November 2026
What improved?
At six months, the PDN-Sensory primary analysis counted at least 50% pain relief in 27/34 stimulation participants (79.4%) versus 2/50 controls (4.0%). The two control responses were imputed for missing follow-up; seven stimulation-assigned patients were excluded. [1]
Limitations and safety
The small, unblinded, manufacturer-funded study stopped early. Four of 34 stimulation participants required further surgery. [1]
What does this mean for patients?
Current diabetes guidance still supports suitable medicines, risk-factor management and foot surveillance. A specialist discussion can bring those strands together when pain remains troublesome. Any device decision should include its practical demands as well as its potential benefit. [2]
Bring your medication history, treatment goals and questions about follow-up. Ask what improvement would make the intervention worthwhile in your circumstances.
Sources
[1] Hurley et al. (2026): PDN-Sensory trial. DOI: 10.2337/dc26-0758. PMID: 42713876. Trial: NCT05777317.
[2] ADA Standards of Care 2026: neuropathy and foot care.
This is a general research summary, not a personal treatment recommendation.